Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season
The Journal of Infectious Diseases · 04.02.2025 · 231 (1) · e123-e131
DOI: 10.1093/infdis/jiae454 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 16.09.2024. Verfasst von Hannah Bahakel und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Ohio. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Immunogenicity, Vaccine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Clinical and Translational Science Awards, NCATS NIH HHS.
Abstract (Originalsprache)
Background
Pediatric hematopoietic cell transplant (HCT) recipients are at high risk for morbidity from influenza virus infection. We demonstrated in a primary phase 2 randomized controlled trial that 2 post-HCT doses of high-dose trivalent influenza vaccine (HD-TIV) given 4 weeks apart were more immunogenic than 2 doses of standard-dose quadrivalent influenza vaccine (SD-QIV). Herein, we present the immunogenicity and safety of influenza vaccination in a consecutive season post-HCT using the same dosing regimen.
Methods
A subcohort of study participants reenrolled and had hemagglutinin inhibition titers measured at baseline and 4 weeks after each vaccine dose in year 2. We estimated geometric mean fold rise in hemagglutinin inhibition titer from baseline for each group and used linear mixed effects models to estimate adjusted geometric mean ratios (comparing HD-TIV vs SD-QIV) for each antigen at each time point. We described systemic and injection site reactions.
Results
A total of 65 subcohort patients participated (33 SD-QIV, 32 HD-TIV). Postvaccine geometric mean fold rise and adjusted geometric mean ratio estimates were higher for both groups following a single influenza vaccine dose in year 2 as compared with 2 doses of the same formulation in year 1. Both groups had similar frequencies of injection site and systemic reactions.
Conclusions
A single dose of HD-TIV or SD-QIV was more immunogenic in year 2 than 2 doses of the same formulation in year 1. Reactogenicity was comparable between groups. One dose of influenza vaccine may be sufficient after a 2-dose schedule in the prior year post-HCT. Clinical Trials Registration NCT02860039 (ClinicalTrials.gov).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Ohio.
- Department of Biostatistics, Vanderbilt University Medical Center.
- Department of Pediatrics, Monroe Carell Jr Children's Hospital at Vanderbilt, and Vanderbilt University Medical Center, Nashville, Tennessee.
- Department of Pediatrics, Children's Mercy Kansas City, Missouri.
- Division of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, and Texas Children's Hospital, Houston.
- Department of Pediatrics, Children's Hospital of Philadelphia, Pennsylvania.
ORCID-Profile: Hannah Bahakel, Zaid Haddadin, Gabriela Maron, Lara Danziger-Isakov
Förderung
- NIAID NIH HHS
- Clinical and Translational Science Awards
- NCATS NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Bahakel, H., Spieker, A. J., Hayek, H., Schuster, J. E., Hamdan, L., Dulek, D. E., Kitko, C. L., Stopczynski, T., Batarseh, E., Haddadin, Z., Stewart, L. S., Stahl, A., Potter, M., Rahman, H., Amarin, J., Kalams, S. A., Bocchini, C. E., Moulton, E. A., Coffin, S. E., …, & Pediatric HCT Flu Study (2025). Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season. The Journal of Infectious Diseases, 231(1), e123-e131. https://doi.org/10.1093/infdis/jiae454
Vancouver
Bahakel H, Spieker AJ, Hayek H, Schuster JE, Hamdan L, Dulek DE, et al. Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season. The Journal of Infectious Diseases. 2025;231(1):e123-e131. doi:10.1093/infdis/jiae454
BibTeX
@article{Bahakel2025,
author = {Bahakel, Hannah and Spieker, Andrew J and Hayek, Haya and Schuster, Jennifer E and Hamdan, Lubna and Dulek, Daniel E and Kitko, Carrie L and Stopczynski, Tess and Batarseh, Einas and Haddadin, Zaid and Stewart, Laura S and Stahl, Anna and Potter, Molly and Rahman, Herdi and Amarin, Justin and Kalams, Spyros A and Bocchini, Claire E and Moulton, Elizabeth A and Coffin, Susan E and Ardura, Monica I and Wattier, Rachel L and Maron, Gabriela and Grimley, Michael and Paulsen, Grant and Harrison, Christopher J and Freedman, Jason and Carpenter, Paul A and Englund, Janet A and Munoz, Flor M and Danziger-Isakov, Lara and Halasa, Natasha and Pediatric HCT Flu Study, Pediatric HCT Flu Study},
title = {Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season},
journal = {The Journal of Infectious Diseases},
year = {2025},
volume = {231},
number = {1},
pages = {e123--e131},
doi = {10.1093/infdis/jiae454}
}
EUVIMED